Lost Password? No account yet? Register

Advertisement

New Media Advertisement
OM PHARMA has signed an exclusive global license agreement for synthetic triacyl compounds PDF Print E-mail
User Rating: / 0
PoorBest 
Written by Administrator   
Friday, 22 February 2008

OM PHARMA enters into worldwide exclusive agreement on triacyls, including OM-197-MP-AC and OM-294-DP, with an important European pharmaceutical company

OM PHARMA has signed an exclusive global license agreement for synthetic triacyl compounds, including OM-197-MP-AC and OM-294-DP with an undisclosed important European pharmaceutical company. 

These novel TLR4 agonists are strong activators of human dendritic cells. Such activity is crucial to the role played by immunological adjuvants for the development of prophylactic and therapeutic vaccines in allergology and other indications. In addition to an advanced preclinical pharmacology programme, these molecules also have a good safety profile, designed to allow their use in phase I clinical trials.

Last Updated ( Friday, 11 April 2008 )
 
< Prev   Next >
[ Back ]

Latest Articles - Overview

Advertisement

Pharmaceutical Machinery & Equipment Convention

Advertisement

CPhL

11.03.2008 | Retailing

Kmart Pharmacy has launch of the American Fare Dollar Program, which offers pharmacy customers a choice of 10 over-the-counter (OTC) medications from Kmart's proprietary American Fare brand for only…     Readmore

Image

09.09.2007 | Outsourcing

The pharmaceutical manufacturers in the United States have attacked the proposed pharma policy of India saying that it would contravene the stated goal of liberalizing the sector, and sought some…     Readmore

Image

09.09.2007 | Homeopathy

The Homeopatic manufacturing units must fulfill the conditions stated by the government of India under 67-G     Readmore

10.07.2008 | FDA

Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics,  has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2…     Readmore

17.07.2008 | Biotechnology

Angel Biotechnology Holdings plc, the biopharmaceutical contract manufacturer, is announced pre-GMP process development programme with Angport Limited. The contract is the first to be signed under the EPhaG relationship…     Readmore

07.10.2008 | Nanotechnology

Cambridge is one of four institutes located outside of Japan which will host a satellite of the 'International Center for Materials Nanoarchitectonics' (MANA). (The University of California, Los Angeles,…     Readmore

20.12.2007 | Packaging

Bilcare Research has launched a product to help check the menace of counterfeit drugs. The product has a label with a unique bar code made out of nanotechnology and…     Readmore